Breaks Categories: News

TuesdaySep 06, 2022 12:33 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Secures FDA and Health Canada Approval for Phase 2 Trial of FSD201

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced its receipt of a “Study May Proceed” letter for the Investigational New Drug (“IND”) application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its phase 2 clinical trial of FSD201. The trial will study the safety and efficacy of FSD201 in patients with chronic widespread musculoskeletal nociplastic pain associated with idiopathic mast cell activation syndrome. “We are delighted to…

Continue Reading

WednesdayAug 31, 2022 12:32 pm

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “This final development milestone marks the completion of a detailed series of goals set between Cybin and Adelia almost two years ago. Our combined teams have executed…

Continue Reading

TuesdayAug 30, 2022 10:48 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Dosing Participants in CYB003 Trial for Treatment of MDD

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced a clinical milestone: the first two participants in its phase 1/2a trial evaluating CYB003 for the treatment of major depressive disorder (“MDD”) have been dosed. According to the announcement, CYB003 is the first-ever novel psilocybin analog to enter clinical development. The company is conducting a randomized, double-blind, placebo-controlled study evaluating people with moderate to severe MDD in which participants will receive two administrations (placebo/active and active/active) with a response assessed at week 3 after first dose and at week 6 after second dose. “To…

Continue Reading

MondayAug 29, 2022 12:19 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending dose (‘MAD’) trial, eight healthy human volunteers were randomly assigned 1:1 to 1 dose of PRV-003 or placebo for five consecutive days,” the article reads. “Evaluated by the Safety Review Committee, no serious adverse events were recorded, and all patients demonstrated normal vital signs, electrocardiogram…

Continue Reading

ThursdayAug 25, 2022 3:44 pm

BioMedNewsBreaks – BioLife Sciences Inc. (BLFE) Expands with Focus on Disruptive Hemp Products

BioLife Sciences (OTC: BLFE) has announced that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on hemp products. According to the update, the company will focus on new and innovative product infusions centered around North American-grown, third-party tested industrial hemp with the intention to provide consumers with an array of new and more effective options. “We are so thrilled that BioLife will be focusing on this stream of business focusing on products in the marketplace, which are not only disruptors, but that are beneficial and useful products for consumers…

Continue Reading

ThursdayAug 25, 2022 11:12 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming H.C. Wainwright Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the H.C. Wainwright 24th annual Global Investment Conference; the elite event is slated for Sept. 12–14, 2022. CYBN CEO Doug Drysdale will present in a virtual fireside chat during the conference. The company announced that his presentation will be available starting Sept. 12 at 7 a.m. ET. An archived copy of the presentation will also be available on Cybin’s website following the event. To view the presentation, visit https://ibn.fm/OUzui   To view the full press release, visit https://ibn.fm/8aXqL About Cybin Inc. Cybin…

Continue Reading

ThursdayAug 18, 2022 11:09 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary drug to treat concussion; this phase involves healthy human subjects. The company noted that the MAD cohort I, which was conducted at Nucleus Network, a leading clinical research organization, indicated the drug was safe and well tolerated. That phase involved eight healthy human volunteers who…

Continue Reading

TuesdayAug 16, 2022 2:13 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted by best-selling author and entrepreneur Dr. Anthony M. Criniti IV (aka “Dr. Finance(R)”). During the interview, Favre discussed how his passion for uncovering a treatment for concussion led him to his current position as a member of Odyssey Health’s sports advisory board. “When I retired…

Continue Reading

TuesdayAug 16, 2022 1:34 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (OTCQB: QSAM) Releases Q2 2022 Financial Report, Corporate Update

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has reported on its financial results for Q2, the period ended June 30, 2022; the company also noted that progress has been shown in its phase 1 clinical program designed to evaluate CycloSam, its proprietary radiopharmaceutical drug candidate for the treatment of metastatic bone cancer. Specifically, the report noted that preliminary evaluation of the first patient dosed in the phase 1 trial suggests promising results with second patient dosing and completion of the first cohort of patients…

Continue Reading

TuesdayAug 16, 2022 11:46 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Results of Annual Meeting of Shareholders

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM)”, today announced voting results for each of the matters presented at the company’s annual shareholders’ meeting. There were 71 shareholders represented in person or by proxy, holding 47,019,721 common shares, representing 28.3% of Cybin’s total issued and outstanding common shares as at the record date for the meeting held on Aug. 15, 2022. The announcement details voting results for each matter presented, including the appointment of Zeifmans LLP as auditor and election of directors. Each of the nominees listed in Cybin’s July 13 management information…

Continue Reading